3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Leukemia, Myeloid, Accelerated Phase
4
Leukemia
4
Blast Crisis
4
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Acute
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Neoplasms by Histologic Type
1
Neoplasms
1
Myeloproliferative Disorders
1
Lymphoma
1
Leukemia, Myeloid
1
Hematologic Diseases
1
Burkitt Lymphoma
1
Bone Marrow Diseases
1
Interventions
pirtobrutinib
3
Cyclophosphamide
3
Azacitidine
3
ibrutinib
2
fludarabine
2
Mycophenolic Acid
2
Lenalidomide
2
zanubrutinib
1
venetoclax
1
ruxolitinib
1
ponatinib
1
nilotinib
1
idelalisib
1
idecabtagene vicleucel
1
fludarabine phosphate
1
cedazuridine
1
cc-486
1
asciminib
1
acalabrutinib
1
Whole-Body Irradiation
1
Vancomycin
1
Tretinoin
1
Tacrolimus
1
Sirolimus
1
Semen Analysis
1
Rituximab
1
Quality of Life
1
Physical Examination
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Diseases
×
ponatinib
×
90 days
×
Clear all
NCT02467270
2026-03-17
OPTIC
Takeda
Phase 2
Completed
283 enrolled
31 charts